Molecular Mechanisms Associated with Antifungal Resistance in Pathogenic Candida Species
Open accessThe DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Abstract
Candidiasis is a highly pervasive infection posing major health risks, especially for immunocompromised populations. Pathogenic Candida species have evolved intrinsic and acquired resistance to a variety of antifungal medications. The primary goal of this literature review is to summarize the molecular mechanisms associated with antifungal resistance in Candida species. Resistance can be conferred via gain-of-function mutations in target pathway genes or their transcriptional regulators. Therefore, an overview of the known gene mutations is presented for the following antifungals: azoles (fluconazole, voriconazole, posaconazole and itraconazole), echinocandins (caspofungin, anidulafungin and micafungin), polyenes (amphotericin B and nystatin) and 5-fluorocytosine (5-FC). The following mutation hot spots were identified: (1) ergosterol biosynthesis pathway mutations (ERG11 and UPC2), resulting in azole resistance; (2) overexpression of the efflux pumps, promoting azole resistance (transcription factor genes: tac1 and mrr1; transporter genes: CDR1, CDR2, MDR1, PDR16 and SNQ2); (3) cell wall biosynthesis mutations (FKS1, FKS2 and PDR1), conferring resistance to echinocandins; (4) mutations of nucleic acid synthesis/repair genes (FCY1, FCY2 and FUR1), resulting in 5-FC resistance; and (5) biofilm production, promoting general antifungal resistance. This review also provides a summary of standardized inhibitory breakpoints obtained from international guidelines for prominent Candida species. Notably, N. glabrata, P. kudriavzevii and C. auris demonstrate fluconazole resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660
Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662 · cited 2×
“Numerous species isolates have been identified as displaying resistance to several antifungals [26–28].”
BackgroundChandra, J., Kuhn, D. M., Mukherjee, P. K., Hoyer, L. L., McCormick, T., & Ghannoum, M. A. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.18.5385-5394.2001 · Cited by 1,578
The cell wall: a carbohydrate armour for the fungal cell
Latgé, J. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2007.05872.x · Cited by 987
Fidel, P. L., Vazquez, J. A., & Sobel, J. D. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.80 · Cited by 953
Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species
Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900 · cited 2×
“However, ERG3 inactivation appeared to minimally contribute to azole resistance in a wide range of studied clinical C. albicans [116].”
BackgroundPfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825
Vermes, A. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.2.171 · Cited by 803
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778 · cited 1×
“Echinocandin resistance is associated with modifications to the FKS1 or FKS2 gene sequences, which code for the β 1–3 glucan synthase enzyme (Figure 3) [156].”
BackgroundPfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ellis, D., Tullio, V., Rodloff, A., Fu, W., & Ling, T. A. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02117-09 · Cited by 718 · cited 1×
“Numerous species isolates have been identified as displaying resistance to several antifungals [26–28].”
BackgroundEpidemiology and risk factors for invasive candidiasis
Yapar, N. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s40160 · Cited by 610 · cited 1×
“This review focuses on infectious Candida species that comprise most reported candidiasis cases, including C. albicans , C. glabrata ( Nakaseomyces glabrata ), C. parapsilosis , C. tropicalis and P. kudriavzevii ( Pichia kudriavzevii ) [13–16].”
BackgroundRamage, G., Rajendran, R., Sherry, L., & Williams, C. (2012) · International Journal of Microbiology · doi:10.1155/2012/528521 · Cited by 583
Candida biofilms on implanted biomaterials: a clinically significant problem
Ramage, G., MartÃnez, J. P., & López-Ribot, J. L. (2006) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2006.00117.x · Cited by 575
Fluconazole resistance in Candida species: a current perspective
Berkow, E., & Lockhart, S. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s118892 · Cited by 542
Resistance to echinocandin-class antifungal drugs.
Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512
Mukherjee, P. K., Chandra, J., Kuhn, D. M., & Ghannoum, M. A. (2003) · Infection and Immunity · doi:10.1128/iai.71.8.4333-4340.2003 · Cited by 511
Our Current Understanding of Fungal Biofilms
Ramage, G., Mowat, E., Jones, B., Williams, C., & Lopez-Ribot, J. (2009) · Critical Reviews in Microbiology · doi:10.3109/10408410903241436 · Cited by 483
Candidiasis and Mechanisms of Antifungal Resistance
Bhattacharya, S., Sae-Tia, S., & Fries, B. C. (2020) · Antibiotics · doi:10.3390/antibiotics9060312 · Cited by 474
Perea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martı́nez, M., Calabrese, D., Sanglard, D., & Patterson, T. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2676-2684.2001 · Cited by 470
Ramage, G. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf049 · Cited by 468
Resistance Mechanisms in Clinical Isolates of Candida albicans
White, T. C., Holleman, S., Dy, F., Mirels, L. F., & Stevens, D. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1704-1713.2002 · Cited by 461
Estimation of Direct Healthcare Costs of Fungal Diseases in the United States
Benedict, K., Jackson, B. R., Chiller, T., & Beer, K. D. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy776 · Cited by 438
Park, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
Putative Role of β-1,3 Glucans in Candida albicans Biofilm Resistance
Nett, J., Lincoln, L., Marchillo, K., Massey, R., Holoyda, K., Hoff, B., VanHandel, M., & Andes, D. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01056-06 · Cited by 407
Sanglard, D., Ischer, F., Parkinson, T., Falconer, D., & Bille, J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2404-2412.2003 · Cited by 398 · cited 1×
“When its expression is inhibited by mutation or deletion, the reduction in toxicity due to the inhibition of toxic diol formation is sufficient to confer resistance in some Candida spp. [113–115].”
BackgroundAndes, D., Nett, J., Oschel, P., Albrecht, R., Marchillo, K., & Pitula, A. (2004) · Infection and Immunity · doi:10.1128/iai.72.10.6023-6031.2004 · Cited by 389
Marichal, P., Koymans, L., Willemsens, S., Bellens, D., Verhasselt, P., Luyten, W., Borgers, M., Ramaekers, F. C. S., Odds, F. C., & Vanden Bossche, H. (1999) · Microbiology · doi:10.1099/00221287-145-10-2701 · Cited by 382
Morschhäuser, J., Barker, K. S., Liu, T. T., Blaß-Warmuth, J., Homayouni, R., & Rogers, P. D. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030164 · Cited by 355 · cited 1×
“Efflux pump overexpression can be further induced by upstream GOF mutations, regulating transcription factor genes (Table 3) [59,125–130, 144, 145].”
BackgroundTumbarello, M., Posteraro, B., Trecarichi, E. M., Fiori, B., Rossi, M., Porta, R., de Gaetano Donati, K., La Sorda, M., Spanu, T., Fadda, G., et al. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00131-07 · Cited by 343
LaFayette, S. L., Collins, C., Zaas, A. K., Schell, W. A., Betancourt-Quiroz, M., Gunatilaka, A. A. L., Perfect, J. R., & Cowen, L. E. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001069 · Cited by 329 · cited 1×
“Finally, the Hsp90 molecule may have a regulatory role with key resistance regulators like Mkc1 from the Pkc1 signaling pathway [184,185].”
BackgroundGarcia-Effron, G., Katiyar, S. K., Park, S., Edlind, T. D., & Perlin, D. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00262-08 · Cited by 323
Garcia-Effron, G., Lee, S., Park, S., Cleary, J. D., & Perlin, D. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00443-09 · Cited by 323
Sanguinetti, M., Posteraro, B., Fiori, B., Ranno, S., Torelli, R., & Fadda, G. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.668-679.2005 · Cited by 319
Pfaller, M. A., Andes, D., Diekema, D. J., Espinel-Ingroff, A., & Sheehan, D. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.09.002 · Cited by 314
Ferrari, S., Ischer, F., Calabrese, D., Posteraro, B., Sanguinetti, M., Fadda, G., Rohde, B., Bauser, C., Bader, O., & Sanglard, D. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000268 · Cited by 295 · cited 2×
“In C. albicans Efflux pumps CDR1, SNQ2, PDH1 and QDR2 implicated in N. glabrata antifungal resistance are regulated by the Pdr1 transcription factor [132,137,150].”
BackgroundA Candida Biofilm-Induced Pathway for Matrix Glucan Delivery: Implications for Drug Resistance
Taff, H. T., Nett, J. E., Zarnowski, R., Ross, K. M., Sanchez, H., Cain, M. T., Hamaker, J., Mitchell, A. P., & Andes, D. R. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002848 · Cited by 291 · cited 2×
“These three enzymes can modify glucan and are involved in its post-translational transport from the cell to the ECM [208,229].”
BackgroundStress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.
Cowen, L. E., & Steinbach, W. J. (2008) · Eukaryotic Cell · doi:10.1128/ec.00041-08 · Cited by 285 · cited 1×
“Finally, the Hsp90 molecule may have a regulatory role with key resistance regulators like Mkc1 from the Pkc1 signaling pathway [184,185].”
BackgroundSanglard, D., Coste, A., & Ferrari, S. (2009) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2009.00578.x · Cited by 285
Vermitsky, J.-P., & Edlind, T. D. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.3773-3781.2004 · Cited by 285 · cited 2×
“GOF mutations within the PDR1 sequence regions linked to azole resistance corresponded to putative inhibitory (aa 312–382) and transcriptional activation (aa 800–1107) domains, as well as aa 539–632, coding for the middle homology region [132,152].”
BackgroundAntifungal Drugs: The Current Armamentarium and Development of New Agents
Robbins, N., Wright, G. D., & Cowen, L. E. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.funk-0002-2016 · Cited by 271
Fungal echinocandin resistance
Walker, L. A., Gow, N. A. R., & Munro, C. A. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.09.003 · Cited by 267 · cited 10×
“Other sections include inner cell wall proteins linked to mannose and galactose polysaccharides [74].”
BackgroundInfluentialGarcia-Effron, G., Park, S., & Perlin, D. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01162-08 · Cited by 256
Genetic Basis of Candida Biofilm Resistance Due to Drug‐Sequestering Matrix Glucan
Nett, J. E., Sanchez, H., Cain, M. T., & Andes, D. R. (2010) · The Journal of Infectious Diseases · doi:10.1086/651200 · Cited by 250
Flowers, S. A., Barker, K. S., Berkow, E. L., Toner, G., Chadwick, S. G., Gygax, S. E., Morschhäuser, J., & Rogers, P. D. (2012) · Eukaryotic Cell · doi:10.1128/ec.00215-12 · Cited by 239 · cited 1×
“Other UPC2 GOF mutations reported from clinical isolates to exhibit azole resistance are listed in Table 2 [100,101,108–110].”
BackgroundPlaine, A., Walker, L., Da Costa, G., Mora-Montes, H. M., McKinnon, A., Gow, N. A. R., Gaillardin, C., Munro, C. A., & Richard, M. L. (2008) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2008.08.003 · Cited by 238 · cited 1×
“C. albicans cells exposed to activators of these pathways were found to have higher chitin contents and decreased caspofungin susceptibility [74,188].”
BackgroundDunkel, N., Liu, T. T., Barker, K. S., Homayouni, R., Morschhäuser, J., & Rogers, P. D. (2008) · Eukaryotic Cell · doi:10.1128/ec.00103-08 · Cited by 236
Vermitsky, J., Earhart, K. D., Smith, W. L., Homayouni, R., Edlind, T. D., & Rogers, P. D. (2006) · Molecular Microbiology · doi:10.1111/j.1365-2958.2006.05235.x · Cited by 233
Rajendran, R., Sherry, L., Nile, C. J., Sherriff, A., Johnson, E. M., Hanson, M. F., Williams, C., Munro, C. A., Jones, B. J., & Ramage, G. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.09.018 · Cited by 228
Balashov, S. V., Park, S., & Perlin, D. S. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01653-05 · Cited by 225
Bhattacharya, S., Esquivel, B. D., & White, T. C. (2018) · mBio · doi:10.1128/mbio.01291-18 · Cited by 210 · cited 1×
“There are 25 different pathway enzymes involved in the formation of ergosterol [85].”
BackgroundNett, J. E., Crawford, K., Marchillo, K., & Andes, D. R. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00227-10 · Cited by 207
Mutations in TAC1B : a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris
Rybak, J. M., Muñoz, J. F., Barker, K. S., Parker, J. E., Esquivel, B. D., Berkow, E. L., Lockhart, S. R., Gade, L., Palmer, G. E., White, T. C., et al. (2020) · mBio · doi:10.1128/mbio.00365-20 · Cited by 202
Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans
Xiang, M.-J., Liu, J.-Y., Ni, P.-H., Wang, S., Shi, C., Wei, B., Ni, Y.-X., & Ge, H.-L. (2013) · FEMS Yeast Research · doi:10.1111/1567-1364.12042 · Cited by 197 · cited 5×
“…can have different biological impacts, depending on whether they are singly present or in combination with other relevant SNPs. Resistance levels can be enhanced when some mutations with moderately low impact alone are present simultaneously with other resistance mutations [86,103,104].”
BackgroundResultInfluentialWatson, P. F., Rose, M. E., Ellis, S. W., England, H., & Kelly, S. L. (1989) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(89)91792-0 · Cited by 197
Moran, G. P., Sanglard, D., Donnelly, S. M., Shanley, D. B., Sullivan, D. J., & Coleman, D. C. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.7.1819 · Cited by 197
Fonzi, W. A. (1999) · Journal of Bacteriology · doi:10.1128/jb.181.22.7070-7079.1999 · Cited by 193
Role for Cell Density in Antifungal Drug Resistance in Candida albicans Biofilms
Perumal, P., Mekala, S., & Chaffin, W. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01237-06 · Cited by 165
Ben-Ami, R., Garcia-Effron, G., Lewis, R. E., Gamarra, S., Leventakos, K., Perlin, D. S., & Kontoyiannis, D. P. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir351 · Cited by 162
Molecular Mechanisms of Primary Resistance to Flucytosine in Candida albicans
Hope, W. W., Tabernero, L., Denning, D. W., & Anderson, M. J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.11.4377-4386.2004 · Cited by 160
Anderson, J. B., Sirjusingh, C., Parsons, A. B., Boone, C., Wickens, C., Cowen, L. E., & Kohn, L. M. (2003) · Genetics · doi:10.1093/genetics/163.4.1287 · Cited by 156
Katiyar, S. K., Alastruey-Izquierdo, A., Healey, K. R., Johnson, M. E., Perlin, D. S., & Edlind, T. D. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00813-12 · Cited by 148 · cited 1×
“Furthermore, a study found a relatively high natural mutation frequency in N. glabrata cells under echinocandin drug pressure for both FKS1 and FKS2, with twice the rate identified for FKS2 [171,172].”
BackgroundThe Quiet and Underappreciated Rise of Drug-Resistant Invasive Fungal Pathogens
Arastehfar, A., Lass-Flörl, C., Garcia-Rubio, R., Daneshnia, F., Ilkit, M., Boekhout, T., Gabaldon, T., & Perlin, D. S. (2020) · Journal of Fungi · doi:10.3390/jof6030138 · Cited by 145
The yeast cell-wall salvage pathway
Popolo, L., Gualtieri, T., & Ragni, E. (2001) · Medical Mycology · doi:10.1080/mmy.39.1.111.121 · Cited by 142
Heilmann, C. J., Schneider, S., Barker, K. S., Rogers, P. D., & Morschhäuser, J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01102-09 · Cited by 142
Antifungal susceptibility of invasive Candida bloodstream isolates from the Asia-Pacific region
Tan, T. Y., Hsu, L. Y., Alejandria, M. M., Chaiwarith, R., Chinniah, T., Chayakulkeeree, M., Choudhury, S., Chen, Y. H., Shin, J. H., Kiratisin, P., et al. (2016) · Medical Mycology · doi:10.1093/mmy/myv114 · Cited by 139
Schubert, S., Barker, K. S., Znaidi, S., Schneider, S., Dierolf, F., Dunkel, N., Aïd, M., Boucher, G., Rogers, P. D., Raymond, M., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01343-10 · Cited by 135 · cited 1×
“Efflux pump overexpression can be further induced by upstream GOF mutations, regulating transcription factor genes (Table 3) [59,125–130, 144, 145].”
BackgroundCandida auris Infection and Biofilm Formation: Going Beyond the Surface
Horton, M. V., & Nett, J. E. (2020) · Current Clinical Microbiology Reports · doi:10.1007/s40588-020-00143-7 · Cited by 132
Pfaller, M. A., Andes, D., Arendrup, M. C., Diekema, D. J., Espinel-Ingroff, A., Alexander, B. D., Brown, S. D., Chaturvedi, V., Fowler, C. L., Ghannoum, M. A., et al. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.03.002 · Cited by 130
Pardini, G., De Groot, P. W. J., Coste, A. T., Karababa, M., Klis, F. M., de Koster, C. G., & Sanglard, D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606361200 · Cited by 121
Znaidi, S., Weber, S., Zin Al-Abdin, O., Bomme, P., Saidane, S., Drouin, S., Lemieux, S., De Deken, X., Robert, F., & Raymond, M. (2008) · Eukaryotic Cell · doi:10.1128/ec.00070-08 · Cited by 119 · cited 2×
“A genome-wide ChIP (chromatin immunoprecipitation) study used to identify Upc2-bound gene promoters identified up to 202 genes, including UPC2 itself [111].”
BackgroundCleary, J. D., Garcia-Effron, G., Chapman, S. W., & Perlin, D. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01568-07 · Cited by 118 · cited 2×
“Significant GOF mutations in the FKS1 gene sequence in clinical isolates have been described, particularly in the hotspot regions of 637–654 and 1345–1365 (Table 4) [74,157,162–168].”
BackgroundAcquired Echinocandin Resistance in a Candida krusei Isolate Due to Modification of Glucan Synthase
Kahn, J. N., Garcia-Effron, G., Hsu, M.-J., Park, S., Marr, K. A., & Perlin, D. S. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00067-07 · Cited by 118
Adherence of Candida albicans to Silicone Induces Immediate Enhanced Tolerance to Fluconazole
Mateus, C., Crow, S. A., & Ahearn, D. G. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.9.3358-3366.2004 · Cited by 113
The genetic code of the fungal CTG clade
Santos, M. A. S., Gomes, A. C., Santos, M. C., Carreto, L. C., & Moura, G. R. (2011) · Comptes Rendus. Biologies · doi:10.1016/j.crvi.2011.05.008 · Cited by 110
Hoot, S. J., Smith, A. R., Brown, R. P., & White, T. C. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00995-10 · Cited by 107 · cited 4×
“However, alternate models exist that involve the sterol regulator, SREBP [107].”
BackgroundInfluentialEvolutionary genomics of yeast pathogens in the Saccharomycotina
Gabaldón, T., Naranjo-Ortíz, M. A., & Marcet-Houben, M. (2016) · FEMS Yeast Research · doi:10.1093/femsyr/fow064 · Cited by 105
Khot, P. D., Suci, P. A., Miller, R. L., Nelson, R. D., & Tyler, B. J. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00997-06 · Cited by 104
Molecular Mechanisms of 5-Fluorocytosine Resistance in Yeasts and Filamentous Fungi
Delma, F. Z., Al-Hatmi, A. M. S., Brüggemann, R. J. M., Melchers, W. J. G., de Hoog, S., Verweij, P. E., & Buil, J. B. (2021) · Journal of Fungi · doi:10.3390/jof7110909 · Cited by 96 · cited 7×
“Membrane permeases encoded by FCY2 (cytosine permease) and other homologs (FCY21 and FCY22) are responsible for the active transport of 5-FC into the cell (Figure 3) [83].”
BackgroundMethodInfluentialGenetic Drivers of Multidrug Resistance in Candida glabrata
Healey, K. R., Jimenez Ortigosa, C., Shor, E., & Perlin, D. S. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01995 · Cited by 93 · cited 3×
“The PDR1 gene may be particularly susceptible to hypermutability due to the coinciding high mutation frequency seen in msh2 (mismatch repair gene 2) [23].”
BackgroundResultAntifungal Resistance in Candida auris: Molecular Determinants
Frías-De-León, M. G., Hernández-Castro, R., Vite-Garín, T., Arenas, R., Bonifaz, A., Castañón-Olivares, L., Acosta-Altamirano, G., & Martínez-Herrera, E. (2020) · Antibiotics · doi:10.3390/antibiotics9090568 · Cited by 93
Echinocandins: A ray of hope in antifungal drug therapy
Grover, N. (2010) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.62396 · Cited by 75 · cited 1×
“Other recent studies highlight the high effectiveness of this class in the treatment of azole-resistant infections [50,76].”
ResultPfaller, M. A., Messer, S. A., Diekema, D. J., Jones, R. N., & Castanheira, M. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.02481-13 · Cited by 74 · cited 1×
“Recent CLSI standards state that caspofungin resistance conferred by hotspot FKS1 mutations is best validated by testing with an additional echinocandin (e.g., anidulafungin or micafungin) or DNA sequencing analysis of the relevant genomic region [175,176].”
BackgroundComparative Genomics for the Elucidation of Multidrug Resistance in Candida lusitaniae
Kannan, A., Asner, S. A., Trachsel, E., Kelly, S., Parker, J., & Sanglard, D. (2019) · mBio · doi:10.1128/mbio.02512-19 · Cited by 63
Zhang, L., Xiao, M., Watts, M. R., Wang, H., Fan, X., Kong, F., & Xu, Y.-C. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1086-6 · Cited by 62 · cited 1×
“Azole-resistant C. parapsilosis and C. dubliniensis strains with increased drug efflux have also been identified [141,142].”
BackgroundSharma, D., Paul, R. A., Rudramurthy, S. M., Kashyap, N., Bhattacharya, S., Soman, R., Shankarnarayan, S. A., Chavan, D., Singh, S., Das, P., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01652-21 · Cited by 60
Whaley, S. G., Zhang, Q., Caudle, K. E., & Rogers, P. D. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01070-18 · Cited by 59
Caplan, T., Polvi, E. J., Xie, J. L., Buckhalter, S., Leach, M. D., Robbins, N., & Cowen, L. E. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.084 · Cited by 56 · cited 1×
“Validated caspofungin tolerance regulators Cas5, Mkc1, Swi4, Gin4, Stt4, Ahr1 and Pkc1 were detected in an alternate screen [182].”
BackgroundMolecular Mechanisms of Resistance to 5-Fluorocytosine in Laboratory Mutants of Candida glabrata
Vandeputte, P., Pineau, L., Larcher, G., Noel, T., Brèthes, D., Chabasse, D., & Bouchara, J.-P. (2011) · Mycopathologia · doi:10.1007/s11046-010-9342-1 · Cited by 55 · cited 1×
“The non-synonymous mutations in the FUR1, FCY1/FCA1 and FCY2 genes described in 5-FC-resistant clinical Candida samples are presented in Table 5 [195–202].”
BackgroundMogavero, S., Tavanti, A., Senesi, S., Rogers, P. D., & Morschhäuser, J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01467-10 · Cited by 49
Costa, C., Ribeiro, J., Miranda, I. M., Silva-Dias, A., Cavalheiro, M., Costa-de-Oliveira, S., Rodrigues, A. G., & Teixeira, M. C. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00526 · Cited by 43
Novel point mutations in the ERG11 gene in clinical isolates of azole resistant Candida species
Silva, D. B. D. S., Rodrigues, L. M. C., Almeida, A. A. D., Oliveira, K. M. P. D., & Grisolia/, A. B. (2016) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/0074-02760150400 · Cited by 42
Vu, B. G., Stamnes, M. A., Li, Y., Rogers, P. D., & Moye-Rowley, W. S. (2021) · PLOS Genetics · doi:10.1371/journal.pgen.1009582 · Cited by 39
Killing Kinetics of Caspofungin, Micafungin, and Amphotericin B against Candida guilliermondii
Cantón, E., Pemán, J., Sastre, M., Romero, M., & Espinel-Ingroff, A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00524-06 · Cited by 37
Jia, Y., Tang, R.-J., Wang, L., Zhang, X., Wang, Y., Jia, X.-M., & Jiang, Y.-Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048369 · Cited by 19
Enhanced Efflux Pump Activity in Old Candida glabrata Cells
Bhattacharya, S., & Fries, B. C. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02227-17 · Cited by 19
Culakova, H., Dzugasova, V., Valencikova, R., Gbelska, Y., & Subik, J. (2015) · Microbiological Research · doi:10.1016/j.micres.2015.03.004 · Cited by 11
Cited by
Lin, W., Peng, Y., Xiang, B., Fang, J., Ye, J., & Guo, P. (2025) · BMC Microbiology · doi:10.1186/s12866-025-04275-y · Cited by 3
“Consequently, echinocandins have emerged as first-line agents for C. glabrata infections [5, 6].”
Metadata
- Authors
- Czajka, K. M., Venkataraman, K., Brabant-Kirwan, D., Santi, S. A., Verschoor, C., Appanna, V. D., Singh, R., Saunders, D. P., & Tharmalingam, S.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2023-11-19
- Volume
- 12
- Issue
- 22
- Pages
- 2655
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W4388833028
- Cited by
- 180
- References
- 97
- FWCI
- 33.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.